{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T21:07:14Z","timestamp":1782421634326,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,9,23]],"date-time":"2013-09-23T00:00:00Z","timestamp":1379894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>\n<jats:list>\n\n<jats:list-item><jats:p>The purpose of the present study was to examine whether cytochrome P450 2C19 (<jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C19) in carriers of the <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>17<\/jats:italic> allele is inhibited <jats:italic>in vivo<\/jats:italic> by oral contraceptives (<jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>).<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Retrospective <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C19 phenotyping according to omeprazole\u00a0:\u00a05\u2010<jats:styled-content style=\"fixed-case\">OH<\/jats:styled-content>\u2010omeprazole molar 3\u00a0h plasma metabolic ratios (<jats:styled-content style=\"fixed-case\">MR<\/jats:styled-content>) from a population (<jats:italic>n<\/jats:italic>\u00a0=\u00a0222) genotyped as <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>1\/<\/jats:italic>*<jats:italic>1<\/jats:italic>,<jats:italic> CYP2C19<\/jats:italic>*<jats:italic>1\/<\/jats:italic>*<jats:italic>17<\/jats:italic> and <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>17\/<\/jats:italic>*<jats:italic>17<\/jats:italic> was analysed. Furthermore, 30 women genotyped as <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>1\/<\/jats:italic>*<jats:italic>1<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a011), <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>1\/<\/jats:italic>*<jats:italic>17<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a011) and <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>17\/<\/jats:italic>*<jats:italic>17<\/jats:italic> (<jats:italic>n<\/jats:italic>\u00a0=\u00a08) were prospectively <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C19 phenotyped during the administration of <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> and again after a minimum 5\u00a0days break from <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content>.<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>We found a significantly higher <jats:styled-content style=\"fixed-case\">MR<\/jats:styled-content> in the <jats:italic><jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C19<\/jats:italic>*<jats:italic>1\/<\/jats:italic>*<jats:italic>1<\/jats:italic> genotype group that took <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a048) compared with women who did not take <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a031; geometric mean 1.37 <jats:italic>vs<\/jats:italic> 0.83, respectively; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). However, in the <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>1\/<\/jats:italic>*<jats:italic>17<\/jats:italic> genotype group, the geometric means of the <jats:styled-content style=\"fixed-case\">MR<\/jats:styled-content> in the 37 women taking <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> and the 20 women not taking <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> were 0.67 and 0.46, respectively (<jats:italic>P\u00a0<\/jats:italic>&gt;\u00a00.05). In the <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>1\/<\/jats:italic>*<jats:italic>1<\/jats:italic> panel of the prospective cross\u2010over study, we found a significantly higher <jats:styled-content style=\"fixed-case\">MR<\/jats:styled-content> while women were taking the <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> compared with the <jats:styled-content style=\"fixed-case\">MR<\/jats:styled-content> during the <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> break (geometric mean 1.21 <jats:italic>vs<\/jats:italic> 0.91, respectively; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0123). However, in the <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>1\/<\/jats:italic>*<jats:italic>17<\/jats:italic> group, the geometric means of the <jats:styled-content style=\"fixed-case\">MR<\/jats:styled-content> with and without <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> were 0.77 and 0.65, respectively, compared with 1.05 and 0.79, respectively, in the <jats:italic><jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C19<\/jats:italic>*<jats:italic>17\/<\/jats:italic>*<jats:italic>17<\/jats:italic> group (<jats:italic>P\u00a0=\u00a0<\/jats:italic>0.20 and 0.17, respectively).<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>In conclusion, we have shown that <jats:styled-content style=\"fixed-case\">OC<\/jats:styled-content> intake inhibits <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C19 in homozygous carriers of the <jats:italic>CYP2C19<\/jats:italic> wild type but that the inhibition is not significant in heterozygous and homozygous carriers of the <jats:italic>CYP2C19<\/jats:italic>*<jats:italic>17<\/jats:italic> allele.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p>","DOI":"10.1111\/1440-1681.12153","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T15:46:49Z","timestamp":1373557609000},"page":"683-688","source":"Crossref","is-referenced-by-count":11,"title":["Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the <i>CYP2C19<\/i>*<i>17<\/i> allele"],"prefix":"10.1111","volume":"40","author":[{"given":"Rasmus S.","family":"Pedersen","sequence":"first","affiliation":[{"name":"Institute of Public Health Clinical Pharmacology University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Noehr\u2010Jensen","sequence":"additional","affiliation":[{"name":"Institute of Public Health Clinical Pharmacology University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Brosen","sequence":"additional","affiliation":[{"name":"Institute of Public Health Clinical Pharmacology University of Southern Denmark Odense Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-003-0819-z"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-008-2291-6"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-321-3_21"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.02.007"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq374"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00541938"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199512000-00004"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100050"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199412000-00001"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.10.002"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03104.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0529-z"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111414451"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100291"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2009.50"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2010.39"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0864-8"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.10.1.43"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0583-6"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0076-4"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0818-1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.03057.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0835-0"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2001.01328.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050615"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.108949"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005280851"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01868.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.3.364"},{"key":"e_1_2_7_31_1","unstructured":"CavacoI BrancaR Lethi\u00f6J Ingelman\u2010SundbergMEvidence for HNRNP L as a specific transcription factor of the CYP2C19*17 allele. In. Proceedings of the 19th International Symposium on Microsomes and Drug Oxidations and 12th European Regional ISSX Meeting 17\u201321 June 2012: Noordwijk Aan Zee The Nederlands. International Society for the Study of Xenobiotics Washington DC. 2012; Abstract A7. Available from:http:\/\/issx.confex.com\/issx\/12euro\/webprogram\/Paper26982.html(accessed 12 August 2013)."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.110.065540"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0657-0"},{"key":"e_1_2_7_34_1","first-page":"356","article-title":"A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S\u2010mephenytoin","volume":"284","author":"Ferguson RJ","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(96)72025-6"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1272-z"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1440-1681.12153","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1440-1681.12153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T07:00:25Z","timestamp":1696316425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1440-1681.12153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,23]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/1440-1681.12153"],"URL":"https:\/\/doi.org\/10.1111\/1440-1681.12153","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,23]]}}}